Clinical Trial Update: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MASCT-I in combination with doxorubicin and ifosfamide as first-line therapy for advanced soft tissue sarcoma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Epithelioid Sarcoma
• Leiomyosarcoma
• Liposarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• IFOSFAMIDE (IFOSFAMIDE)
• MASCT-I

Snippet

Sponsor: HRYZ Biotech Co. | Conditions: Leiomyosarcoma, Liposarcoma | Phase 2 | Status: RECRUITING